Celcuity's cancer drug approved — its stock fell instead

The stock drop is the more interesting part of this story. Everyone expected this drug to get approved, so that news was already reflected in the share price. What surprised investors was the timeline — the company won't actually start selling the drug for another two months. That gap between "approved" and "available" is exactly where small biotech companies stumble, and this one just walked right into it.

Approval and actually being ready to sell a drug are two different things, and Celcuity has the first without much of the second. Several analysts think the company should just sell the drug to a bigger pharmaceutical company that already has a sales team in place — hard to argue with. Worth remembering too: that 76% figure is Celcuity's own reported result, measured against a single older drug alone, not against every option a patient might otherwise have.

What to watch: whether the launch actually happens on schedule this fall, and whether Celcuity files to expand the drug to a second, larger group of patients who don't currently qualify for it — that filing would roughly double how many people could eventually use it.